- Home
- TPST vs DETX Comparison
TPST vs DETX Comparison
Compare TPST & DETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | DETX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 23.9M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | DETX |
|---|---|---|
| Price | $1.25 | N/A |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 88.4K | N/A |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | N/A |
| 52 Week High | $12.22 | N/A |
Technical Indicators
Market Signals| Indicator | TPST | DETX |
|---|---|---|
| Relative Strength Index (RSI) | 30.75 | N/A |
| Support Level | $1.23 | N/A |
| Resistance Level | $2.48 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.30 | 0.00 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.